In somatotropinomas, a higher expression of the SSTR2 gene was associated with higher efficacy of octreotide compared with pasireotide, whereas tumors with a higher level of SSTR5 tended to respond better to pasireotide [17]. The gene discussed is SSTR5; the disease is growth hormone-producing pituitary gland neoplasm.